Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of BMS-986165 on Oral Contraceptive PK in Healthy Females
NCT03262727Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2017
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of deucravacitinib in plaque psoriasis, systemic lupus erythematosus (SLE), psoriatic arthritis (PsA) and 1 more, sponsored by Bristol Myers Squibb. Primary endpoints: Maximum Plasma Concentration at 1 day and Area Under the Plasma Concentration-Time Curve at 1 day. Started Sep 2017; status: completed.
02
Drugs
deucravacitinib
03
Conditions
plaque psoriasissystemic lupus erythematosus (SLE)psoriatic arthritis (PsA)inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT03262727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03262727.